Hi Sanfran and all.
I'm just catching up. Thanks to everyone for the excellent posts. So what I'm seeing is the success of a per reviewed and approved journal article in Atherosclerosis, a Zenith update and presentation in the USA as well as other presentations to scientists and investors and none of this has had any positive impact of share price...and it won't...unless some key partner begins to listen. Don has backed out of the Zenith IPO particularly regarding the NASDAQ. These types of things do not provide much confidence for potential investors. Backing away from the NASDAQ for Zenith is a clear signal that Don does not care about investor market breadth and perhaps he is afraid of the USA markets and regulations.
Sanfran, your question to management "What is management's plan for increasing shareholder knowledge and interest in this stock?" is to me the absolute key issue for shareholders of RVX between now and 2019 when BETonMACE results are announced. We all know that many positive events could happen in the next 3 years including more regional deals, BP taking notice of the post hoc analysis, the momentum and successes of epigenetics as a science, the orphan trials, the FDA approved trial at Zenith (which lends credibility to rvx-208), etc.
Recently I've been reading the articles in the Globe about the gutting of Canadian biotech R & D that started with Brian Mulroney's original free trade deal in which pharma R & D was to remain at 20% and is now down to between 5% and 8%. It is well know that R & D moves to the locations of the head offices, which given foreign ownership, has moved out of Canada. There is an entire area in Montreal that was a hub of pharma R & D which is now boarded up.
So where am I headed. It seems to me that this tiny little Canadian based biotech called RVX and based in Calgary with 15 years of success should be showcased as a potential Canadian biotech innovator. Seems like a stretch but there is huge communications leverage in this. With the right communications specialists in place this company provides a relatively continuous flow of interesting information not just for Canadian investors but also in the USA and other countries.
Sadly RVX completely lacks communications expertise and they do not have the capability nor interest in getting their message out other than to tiny little pockets of scientists and a few specialized investors and these investors will wait until early 2018 or later before they move in.
Resverlogix has a great story to tell and most unfortunately it will never be told. We all live within our own paradigms and the RVX paradigm is like an "academic box". They may even be too modest to champion their success story.
Anyway, it will remain a story untold until someone else comes in and grabs the value.
GLTA...we'll need it. It is an excellent buying time. Big money will be made.
Toinv
